Showing results (1381-1390 of 5,535) with videos related to

Sort By:
Pageof 554
Inflammatory Bowel Diseases|November 27, 2001
Clinical outcome of Crohn's disease: analysis according to the vienna classification and clinical activityF T Veloso, J T Ferreira, L Barros, et al.
Inflammatory Bowel Diseases|November 27, 2001
Proximal Crohn's disease: review of the clinicopathologic features and therapyR A van Hogezand, A M Witte, R A Veenendaal, et al.
Inflammatory Bowel Diseases|March 27, 2003
The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteriaLaurie M Edmond, Mark J Hopkins, Elizabeth A Magee, et al.
Inflammatory Bowel Diseases|March 27, 2003
Experimental colitis in rats with portal hypertension and liver diseaseZvi Ackerman, Fanny Karmeli, Patrizia Cohen, et al.
Inflammatory Bowel Diseases|March 20, 2021
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical ProgramBruce E Sands, Millie D Long, Walter Reinisch, et al.
Inflammatory Bowel Diseases|November 18, 2021
Current Trends in IBD-Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling SystemYunki Y Yau, Valerie C Wasinger, Robert P Hirten, et al.
Inflammatory Bowel Diseases|November 18, 2021
Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel DiseasesYi Li, Jianping Chen, Andrew A Bolinger, et al.
Inflammatory Bowel Diseases|November 6, 2021
Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn's DiseaseXavier Roblin, Adrian Serone, Oh Kyu Yoon, et al.
Inflammatory Bowel Diseases|December 1, 2021
Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide DataSimon Kjeldsen, Jan Nielsen, Bente Mertz Nørgård, et al.
Inflammatory Bowel Diseases|December 1, 2021
Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized TrialWenhui Zhang, Astrid Scalori, Franklin Fuh, et al.
Pageof 554